Renovorx Stock Performance
| RNXT Stock | USD 1.30 0.02 1.52% |
On a scale of 0 to 100, RenovoRx holds a performance score of 14. The company holds a Beta of -0.0552, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning RenovoRx are expected to decrease at a much lower rate. During the bear market, RenovoRx is likely to outperform the market. Please check RenovoRx's potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether RenovoRx's historical price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in RenovoRx are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, RenovoRx unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.2 M | |
| Total Cashflows From Investing Activities | -12 K |
RenovoRx Relative Risk vs. Return Landscape
If you would invest 95.00 in RenovoRx on April 21, 2025 and sell it today you would earn a total of 35.00 from holding RenovoRx or generate 36.84% return on investment over 90 days. RenovoRx is currently generating 0.5411% in daily expected returns and assumes 2.9319% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than RenovoRx, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RenovoRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RenovoRx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as RenovoRx, and traders can use it to determine the average amount a RenovoRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1846
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RNXT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.93 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average RenovoRx is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RenovoRx by adding it to a well-diversified portfolio.
RenovoRx Fundamentals Growth
RenovoRx Stock prices reflect investors' perceptions of the future prospects and financial health of RenovoRx, and RenovoRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RenovoRx Stock performance.
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (15.79) % | ||||
| Current Valuation | 33.98 M | ||||
| Shares Outstanding | 36.57 M | ||||
| Price To Book | 3.67 X | ||||
| Price To Sales | 198.10 X | ||||
| Revenue | 43 K | ||||
| EBITDA | (10.97 M) | ||||
| Cash And Equivalents | 10.77 M | ||||
| Cash Per Share | 1.19 X | ||||
| Total Debt | 278 K | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (9.12 M) | ||||
| Earnings Per Share | (0.41) X | ||||
| Total Asset | 8.12 M | ||||
| Retained Earnings | (50.22 M) | ||||
About RenovoRx Performance
Assessing RenovoRx's fundamental ratios provides investors with valuable insights into RenovoRx's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the RenovoRx is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.Things to note about RenovoRx performance evaluation
Checking the ongoing alerts about RenovoRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RenovoRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RenovoRx may become a speculative penny stock | |
| The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 146 K. | |
| RenovoRx currently holds about 10.77 M in cash with (9.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19. | |
| RenovoRx has a frail financial position based on the latest SEC disclosures |
- Analyzing RenovoRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RenovoRx's stock is overvalued or undervalued compared to its peers.
- Examining RenovoRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RenovoRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RenovoRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RenovoRx's stock. These opinions can provide insight into RenovoRx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.